Pharma Now - Empowering Pharma Leadership’s Post

𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝗚𝗹𝗼𝗯𝗮𝗹 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 𝘁𝗼 2028 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲-https://lnkd.in/dMtUyZqT The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. Biosimilars Council Biosimilars Forum The Center for Biosimilars Biogen Sandoz Amneal Pharmaceuticals Organon Fresenius Kabi USA Kashiv BioSciences LLC Impax Laboratories Cromos Pharma Association for Accessible Medicines Cytovance Biologics Oncobiologics Inc. mAbxience ADVANZ PHARMA ASPHALION Alvotech Lek Pharmaceuticals Kymos Group Napp Pharmaceuticals Limited SteinCares Sandoz Canada Gedeon Richter Pharma GmbH

#CTS2024 We kicked off the evening with Cedric Francois, Co-Founder and CEO of Apellis Pharmaceuticals and Pascal Deschatelets, Co-Founder and Chief Operating Officer of Apellis Pharmaceuticals. They shared the challenges and successes encountered in drug discovery and development, leading to the launch of the first therapy for geographic atrophy. #CTSRetina #CTSRetina2024

𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 17.8% 𝗳𝗿𝗼𝗺 2023 𝘁𝗼 2028 Download Free Sample Report-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 Sandoz Actavis plc (now Allergan) Fresenius Kabi mAbxience Mundipharma Novartis Italia Alvotech Amgen Italia Novartis Portugal     Polpharma Biologics     Prescient Lek Pharmaceuticals 3P Biopharmaceuticals Napp Pharmaceuticals Limited Synexa Life Sciences Novartis UK Astrea Bioseparations Thornton & Ross  Celonic Group  Egualia – Industrie Farmaci Accessibili Celltrion Healthcare Italia    Amgen Deutschland      ADVANZ PHARMA    ASPHALION Northway Biotech    Antibody Analytics      Novartis Norge QUINTA-ANALYTICA Xbrane Biopharma AB Selexis SA pbserum | Proteos Biotech Profarma Novartis Belux Kymos Inceptua Group Gedeon Richter Pharma GmbH BAP Pharma Formycon AG Eurofins BioPharma Product Testing Netherlands Organon Central Northern Europe

𝗕𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁 𝘁𝗼 𝗴𝗿𝗼𝘄 𝗮𝘁 𝗮 17.8% 𝗳𝗿𝗼𝗺 2023 𝘁𝗼 2028 Download Free Sample Report-https://lnkd.in/gkMUtteS The global biosimilars market in terms of revenue was estimated to be worth $29.4 billion in 2023 and is poised to reach $66.9 billion by 2028, growing at a CAGR of 17.8% from 2023 to 2028. 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 Sandoz Actavis plc (now Allergan) Fresenius Kabi mAbxience Mundipharma Novartis Italia Alvotech Amgen Italia Novartis Portugal     Polpharma Biologics     Prescient Lek Pharmaceuticals 3P Biopharmaceuticals Napp Pharmaceuticals Limited Synexa Life Sciences Novartis UK Astrea Bioseparations Thornton & Ross  Celonic Group  Egualia – Industrie Farmaci Accessibili Celltrion Healthcare Italia    Amgen Deutschland      ADVANZ PHARMA    ASPHALION Northway Biotech    Antibody Analytics      Novartis Norge QUINTA-ANALYTICA Xbrane Biopharma AB Selexis SA pbserum | Proteos Biotech Profarma Novartis Belux Kymos Inceptua Group Gedeon Richter Pharma GmbH BAP Pharma Formycon AG Eurofins BioPharma Product Testing Netherlands Organon Central Northern Europe

Voyageur Pharmaceuticals CEO Brent Willis speaks with Lyndsay Malchuk from Stockhouse about a major milestone: signing an LOI for a strategic collaboration with a multinational partner. The Multinational Pharmaceutical company is ranked in the top five contrast agent suppliers in the world, signalling and solidifying Voyageur’s importance in the global contrast agent market - take a look.

Progressive Supranuclear Palsy Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Woolsey Pharma, Asahi Kasei Pharma, AlzProtect, Amylyx Pharma, Transposon: The Key Progressive Supranuclear Palsy Companies in the market include – Woolsey Pharmaceutical, Asahi Kasei Pharma, AlzProtect, Amylyx Pharmaceuticals, Transposon Therapeutics, Oncolys Biopharma’s, Ferrer/Asceneuron, GemVax & Kael, Ferrer Internacional S.A., Allon Therapeutics, Amylyx Pharmaceuticals, EmeraMed, and others.   DelveInsight’s “Progressive … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Ligand Pharmaceuticals to Acquire APEIRON Biologics AG for €92 Million Ligand Pharmaceuticals recently announced that it has entered into a definitive agreement to acquire Apeiron Biologics AG, which holds royalty rights to Qarziba (dinutuximab beta) for the treatment of high-risk neuroblastoma, for €92 million ($100 million) in cash. Ligand will pay Apeiron shareholders additional consideration based on future commercial and regulatory events, including up to €25.9 million ($28 million) if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively. Apeiron is known for its innovative approaches in #immunooncology and received marketing approval from the European Medicines Agency for Qarziba in 2017 for the treatment of high-risk #neuroblastoma. Ligand Pharmaceuticals is a US-based #biopharmaceutical company supporting the clinical development of high-value medicines. Read more on #CMI online: https://lnkd.in/eAei4c_K

We are thrilled to share the exciting news about a new partnership between Gubra and Boston based Amylyx Pharmaceuticals to develop a novel long-acting GLP-1 receptor antagonist.     “We are pleased to partner with Amylyx to advance GLP-1 receptor antagonism research. This collaboration and development agreement is an example of leading pharmaceutical companies partnering with us for our machine learning-based peptide drug discovery platform. This is yet another testimony that our streaMLine platform can be used to develop peptide drug candidates for a very broad range of diseases,” said Henrik Blou, CEO of Gubra.    Read the full press release here: https://lnkd.in/d97gV7KV Read more about our ML/AI-driven peptide drug discovery platform streaMLine here: https://lnkd.in/e_QUpZXw   #Collaboration #Biotech #DrugDiscovery #PeptideTherapeutics #GLP1ReceptorAntagonist 

Biosimilars, which are a subgroup of biologics, are similar to generics drugs in that both are compared to an original reference product. This means they are nearly identical to an approved biologic medicine and have the same mechanism of action and therapeutic effect as the reference product. Similar to generic drugs, biosimilars help to provide patients more affordable treatment options while retaining the same levels of quality found in name-brand biologics. Biosimilars are currently approved for many biologic reference products, including (but not limited to): Actemra, Avastin, Epogen/Procrit, Enbrel, Eylea, Humira, Herceptin, Lantus, Lucentis, Neulasta, Neupogen, Prolia and Xgeva, Remicade, Rituxan, Soliris, Stelara, Tysabri. We are pleased to announce the release of a new infographic in partnership with the FDA that serves as a resource for healthcare practitioners to better inform patients about the quality attributes of FDA-approved biosimilar products. For more information, view the infographic below ⤵️ #USPScience #Biosimilars

PD-(L)1 Inhibitors Top Abstracts about to reveal at ASCO 2024 At ASCO 2024, leading pharmaceutical giants including AstraZeneca, Merck Healthcare, Bristol Myers Squibb, BeiGene, Akeso, Hengrui Pharma Co.,Ltd, and Qilu Pharmaceuticals are poised to unveil initial, updated, and final findings. The forthcoming session generates high anticipation as it will reveal primary results from the Phase III CheckMate-9DW study, aiming to introduce a potential treatment avenue for enhancing outcomes in hepatocellular cancer, potentially surpassing established tyrosine kinase inhibitors. Notably, results from bi-specific PD-1 inhibitors like Acasunlimab (PD-1 X 4-1BB) and IBI363 (PD-1 and IL-2) will draw considerable attention. Moreover, insights from Chinese pharmaceutical companies are eagerly awaited as well. Unlock Exclusive Expert Insights and Comprehensive Analysis of ASCO 2024 with DelveInsight Business Research LLP - https://lnkd.in/gb4amxnj #ASCO24 #ASCO2024 #PharmaUpdates #ClinicalTrials #CheckMate9DW #HepatocellularCancer #BiSpecificInhibitors #MedicalResearch #CancerTreatment #BiotechNews #ChinesePharma #pd1 #inhibitors #Acasunlimab